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Background: The spectrum of BRCA1/2 genetic variation in breast-ovarian cancer patients has been scarcely
investigated outside Europe and North America, with few reports for South America, where Amerindian founder
effects and recent multiracial immigration are predicted to result in high genetic diversity. We describe here the
results of BRCA1/BRCA2 germline analysis in an Argentinean series of breast/ovarian cancer patients selected for
young age at diagnosis or breast/ovarian cancer family history.
Methods: The study series (134 patients) included 37 cases diagnosed within 40 years of age and no family history
(any ethnicity, fully-sequenced), and 97 cases with at least 2 affected relatives (any age), of which 57 were
non-Ashkenazi (fully-sequenced) and 40 Ashkenazi (tested only for the founder mutations c.66_67delAG and
c.5263insC in BRCA1 and c.5946delT in BRCA2).
Discussion: We found 24 deleterious mutations (BRCA1:16; BRCA2: 8) in 38/134 (28.3%) patients, of which 6/37
(16.2%) within the young age group, 15/57 (26.3%) within the non-Ahkenazi positive for family history; and 17/40
(42.5%) within the Ashkenazi. Seven pathogenetic mutations were novel, five in BRCA1: c.1502_1505delAATT,
c.2626_2627delAA c.2686delA, c.2728 C> T, c.3758_3759delCT, two in BRCA2: c.7105insA, c.793 + 1delG. We also
detected 72 variants of which 54 previously reported and 17 novel, 33 detected in an individual patient. Four
missense variants of unknown clinical significance, identified in 5 patients, are predicted to affect protein function.
While global and European variants contributed near 45% of the detected BRCA1/2 variation, the significant fraction
of new variants (25/96, 26%) suggests the presence of a South American genetic component.
This study, the first conducted in Argentinean patients, highlights a significant impact of novel BRCA1/2 mutations
and genetic variants, which may be regarded as putatively South American, and confirms the important role of
founder BRCA1 and BRCA2 mutations in Argentinean Ashkenazi Jews.
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Hereditary breast cancer accounts for 5-10% of all BC
cases [1] and is characterized by dominant inheritance,
premenopausal diagnosis, more severe course, bilateral-
ity and frequent association with ovarian cancer (OC)
[2]. The identification of the two major hereditary
breast/ovarian cancer genes, BRCA1 (17q21, MIM*
113705) in 1994 [3] and BRCA2 (13q14, MIM* 600185)
in 1995 [4], led to a new era in the diagnosis of inherited
high predisposition to breast and ovarian cancer [5,6].
Breast-ovarian cancer (BOC)-causing mutations and
other genetic variants are distributed along the entire
coding and non-coding regions of BRCA1 and BRCA2,
and more than 3400 gene variants have been described
in the Breast Cancer Information Core (BIC) [7]. New
variants continue to be detected worldwide, mostly in
BRCA1.
The prevalences of BRCA1/BRCA2 mutations in BOC
patients with early onset (EO) and/or BOC family history
(FH) appear to be similar across race/ethnicity, but there
is evidence of important racial and/or geographic differ-
ences in the spectrum of BRCA1/2 genetic variation, in-
cluding pathogenic mutations and variants of uncertain
significance. These differences may reflect population
history and genetic drifts, and could have a significant im-
pact on genetic counselling, genetic testing, and follow-up
care [8]. A typical example is provided by the case of Ash-
kenazi Jews, where three founder mutations: BRCA1
c.66_67delAG BRCA1 c.5263insC, and BRCA2 c.5946delT
account for most of familial breast-ovarian cancer [9].
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews
in Israel: frequency and differential penetrance in ovarian
cancer and in breast-ovarian cancer families [10].
BRCA1/2 mutation status in subsets of BOC patients
selected for age, BOC family history and ethnicity has
been scarcely investigated outside Europe and North
America [5,11-15], with few reports for South America,
where Native American founder effects and the complex
multiracial demography of recent immigration are pre-
dicted to result in high genetic variation[16]. Indeed, re-
cent studies point to a role of Native American ancestryTable 1 Inclusion criteria for the probands
Group (n) Criteria
EO (37) Onset of cancer ≤40 years
Ashk-FH (40) Onset of cancer ≤40 years wi
Onset of cancer >40 years wi
FH (57) Onset of cancer ≤40 years wi
Onset of cancer >40 years wi
Total
n: total number of probands per group. EO: Early onset; Ashk: Ashkenazi; FH: Famil
or ovarian cancer.in BRCA1/2 disease patterns in Central and Northern
America [17-22]. Epidemiological data indicate that in
Argentina BC incidence [23] and mortality rates [24] are
among the highest in the world. The historical records
and epidemiological and molecular studies point to vari-
able degrees of admixture among European, mainly
Spanish and Italian, and Native American components in
more than 50% of the Argentinean population [16,25].
Regarding autosomal evidence of admixture, the relative
European, Native American, and West African genetic
contributions to the Argentinean gene pool were esti-
mated to be 67.55%, 25.9%, and 6.5%, respectively [7].
Our study is the first report describing BRCA1/BRCA2
gene variants in Argentinean BOC patients, and high-
lights a significant impact of novel mutations and gen-
etic variants which may be regarded as putatively South
American. On the other hand, we confirm the key role
of founder BRCA1 and BRCA2 mutations in Argenti-
nean Ashkenazi Jews.Methods
The study includes 134 BOC probands selected either for
age at cancer diagnosis or for family history (FH), accord-
ing to the criteria listed in Table 1. The patients selected
for diagnosis within 40 years of age and no BOC FH (EO
patients, any ethnicity) included 37 cases (21 with BC, 13
with OC, 3 with BOC; age range 12–40 years, mean age
31.0 ± 7.5 years). The FH patients (any age, 97 cases over-
all), selected based on the presence of at least two BOC-
affected 1st or 2nd degree relatives, included 57 non-
Ashkenazi patients (32 with BC, 18 with OC, 7 with
BOC, age range 26–71 years, mean 44.6 ± 10.9 years),
and 40 Ashkenazi patients (32 with BC, 6 with OC and 2
with BOC, age range: 32–64 years, mean age
47.1 ± 9.9 years) (Tables 1 and 2). The Ashkenazi subset
was tested only for the panel of the three founder Ash-
kenazi mutations (c.66_67delAG (reported in BIC as
185delAG), and c.5263insC (in BIC as 5382insC) in
BRCA1 and c.5946delT (in BIC as 6174delT) in BRCA2);
all the other cases were fully sequenced.Number of probands
37
th family history 12
th family history 28
th family history 31
th family history 26
134
y history, defined as: at least 2 members of 1st or 2nd degree with breast and/
Table 2 Summary of the mutations detected
Total patients = 134 (group) Age at diagnosis (n) Family history BRCA1 mutation (%) BRCA2 mutation (%) % of mutated
37 (EO) ≤40 years (37) No 4 (10.8) 2 (5.4) 16.2
40 (Ashk-FH) ≤40 years (12) Yes 3 (25.0) 4 (33.3) 58.3
>40 years (28) Yes 6 (21.4) 4 (14.3) 35.7
57 (FH) ≤40 years (31) Yes 3 (9.7) 3 (9.7) 19.4
>40 years (26) Yes 7 (26.9) 2 (7.7) 35.8
EO: Early onset; Ashk: Ashkenazi; FH: Family History.
Total coding BRCA1-2 sequencing was performed for the patients in all groups except.
the Ashkenazi patients which were tested for the panel of three mutations.
(n): number of probands analyzed.
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to the Laboratory HRDC of the Department of Biochem-
istry, University of Buenos Aires, and were also recruited
at the Centro de Estudios Medicos e Investigaciones
Clinicas (CEMIC). Study eligibility required signing an
informed consent as a result of the routine procedures
for genetic analysis. This study was approved by the Eth-
ics Committee of the Sociedad Argentina de Investiga-
ción Clínica.
Genomic DNA was isolated using the QIAamp DNA
blood purification kit (Qiagen, www.qiagen.com). The
coding sequences and exon-intron boundaries of the
BRCA1-2 genes were analyzed by amplification using
polymerase chain reaction (PCR) with alternative pri-
mers to avoid false results due to polymorphisms
[26,27], followed by direct sequencing of at least 55
amplicons, to ensure overlapping of the segments. Se-
quencing was performed using either an Applied Biosys-
tems 3730xl DNA Analyzer or an Applied Biosystems
ABI PRISM W 310 Genetic Analyzer. Homozygosis (HO)
was confirmed by alternative sequencing in exonic and/
or intronic regions. The three Ashkenazi mutations were
tested as described [28]. Variants nomenclature follows
the guidelines of the Human Genome Variation Society
(HGVS). Tables provide lists including also the nomen-
clature of the Cancer Information Core Internet Website
(BIC), April 2012.
Effects of the missense mutations that resulted not
reported or recorded as clinically unknown (CU) in the
BIC were predicted by virtual analyses of functional
compatibility for aminoacid changes using two pro-
grams: Align-GVGD (http://agvgd.iarc.fr/) [29] and SIFT
(http://sift.bii.a-star.edu.sg/) [30].
Results and discussion
We describe for the first time in Argentina the results of
BRCA1/BRCA2 germline analysis in 134 BOC probands
selected either for diagnosis within 40 years of age (37
cases) or for FH (97 cases) (Tables 1 and 2). The latter
included 40 Ashkenazi patients, tested only for the three
founder Ashkenazi mutations [28]. All the other cases
were fully sequenced.Overall 96 mutations and sequence variants, of which
53 in BRCA1 and 43 in BRCA2, were identified in 94/
134 patients analyzed. Mutation types, effects, carrier
frequencies, worldwide occurrences and relevant refer-
ences are listed in online Additional file 1: Tables S1 and
Additional file 2: Table S2. The sequence variants were
classified as pathogenic based on literature data and/or
when predicted to truncate/inactivate the protein
product.
Among the 53 sequence variants identified in BRCA1
15 are novel and 17 clinically unknown, 14 introduce a
stop codon; 22 are missense substitutions (Additional
file 1: Table S1). With regard to the 43 BRCA2 muta-
tions, 9 are novel, 17 clinically unknown, 6 introduce a
stop codon; 15 are missense substitutions and one is
predicted to result in an aberrant splice (Additional file
2: Table S2). The truncating mutations and the novel
non-truncating variants predicted to affect the BRCA1
and BRCA2 gene products are described in Table 3.
Synonyms, intronic and polymorphic BRCA1 and
BRCA2 variants ranged from 4 to 33 per individual
patients and were detected in all the 94 fully-sequenced
cases (Additional file 1: Table S1 and Additional file 2:
Table S2). Notably, 34 variants are listed in BIC as of
clinically unknown importance, and of these 14 were
identified in unique patients (Additional file 1: Table S1
and Additional file 2: Table S2).
Overall, a total of 24 bona fide pathogenetic muta-
tions, 16 in BRCA1 and 8 in BRCA2, were detected in
38/134 cases (28.4%), including: a) 6/37 (16.2%) fully-
sequenced patients in the group within 40 years of age;
b) 15/57 (26.3%) fully-sequenced non-Ashkenazi FH
patients; c) 17/40 (42.5%) Ashkenazi FH patients, ana-
lyzed for the three Ashkenazi mutations only (Table 2).
The pathogenetic mutations were more frequent in
BRCA1 (23/38, 60.5%) than in BRCA2 (15/38, 39.5%),
which is in agreement with literature data [31].
The Ashkenazi-FH patients with age ≤40 years showed
the highest frequency of pathogenetic BRCA1 and BRCA2
mutations, i.e., 58.3% (for BRCA1 16.7% in c.66_67delAG
and 8.3% in c.5263insC and 33.3% for BRCA2 c.5946delT),
in agreement with literature frequencies [28,32]. The
Table 3 BRCA1/BRCA2 truncating mutations, novel and non-truncating variants affect the gene products



















2 E23VfsX16 Stop cod39 c.66_67delAG 185delAG D AB54 Br(37) Br Ashk-EO-FH Ashkenazi
AB60 Br(40) Br Ashk-EO-
AB77 Ov (44) Br, Ov FH Ashk-
AB68 Ov (44) Br, Ov FH Ashk-
AB76 Br (49) Br FH Ashk-
AB81 Br (52) Br FH Ashk-
AB87 Ov (60) Br, Ov FH Ashk-FH
2 E23KfsX18 Stop cod40 c.67insA 186insA D AB82 Br (34) Br EO-FH NE/ME
5 C61G p. Cys61Gly c.181 T >G 300 T > C D AB75 Br (49) Br FH E
5 R71G p. Arg71Gly c.211A>G 330A>G D AB64 Br (43) Br FH E
7 E143X p. Glu143Stop c.427 G> T 546 G> T D AB46 Br (33) Br, Ov,
Pa, Pr
EO-FH E
11 S267KfsX19 Stop cod285 c.797_798delTT 916delTT D AB36 Br-Ov (46) Br FH C, L-A E, N-A
11 K501Kfs30 Stop cod530 c.1502_1505delAATT 1621delAATT NR AB20 Br (32) No EO Argentina
11 R504VfsX28 Stop cod531 c.1510delC 1629delC D AB40 Br (30) Br EO-FH E
11 E836GfsX2 Stop cod837 c.507_2508delAA 2626delAA NR AB67 Br (50) Br FH Argentina
11 S896Vfs104 Stop cod999 c.2686delA 2805delA NR AB85 Br (55) Br FH Argentina
11 Q910X p. Gln910Stop c.2728 C> T 2847C> T NR AB84 Ov (55) Br, Ov,
Co
FH Argentina
11 R1203X p. Arg1203Stop c.3607C> T 3726C> T D AB8 Ov (25) No EO C, L-A
11 E1210RfsX8 Stop cod1218 c.3627insA 3746insA D AB21 Br-Ov (33) No EO C, L-A, As
11 S1253X p. Ser1253Stop c.3758_3759delCT 3877delCT NR AB17 Br (31) No EO Argentina
17 T1677IfsX2 Stop cod1678 c.5030_5033delCTAA 5149delCTAA D AB79 Br (51)* Br, Ov,
Pa, Pr
FH E
20 S1755PfsX75 Stop cod1829 c.5263insC 5382insC D AB55 Br (49) Br Ashk-FH
Ashk-EO-FH
E, Ashkenazi
AB97 Br (38) Br
BRCA2
9 - Splice defect c.793+1delG IVS9+ 1delG NR AB99 Br (31) Br EO-FH Argentina
11 N955KfsX5 Stop cod959 c.2808_2811delACAA 3036delACAA D AB78 Br (50) Br FH E, L-A
11 S1982RfsX22 Stop cod2003 c.5946delT 6174delT D AB43 Br (32) Br-male Ashk-EO-FH Ashkenazi
AB47 Br (33) Br-male Ashk-EO-
AB69 Br/Ov (45) Br-male FH Ashk-FH
AB57 Br (39) Br, Pa, Ashk-EO-
AB71 Br (46) Ov Pr, FH Ashk-
AB74 Br (48) Br FH Ashk-
AB95 Br (36) Br FHAshk-
AB96 Br (60) Br EO-FH
Ashk-FH
11 K1213X p. Lys1213Stop c.6037A> T 6265A> T D AB34 Br (40) No EO E
11 S1882X p. Ser1882Stop c.5644C>G 5872C>G D AB117 Br (50) Br, Pr FH E
11 Y1894X Stop cod1894 c.5909insA 6137insA D AB92 Br (31) Br EO-FH E
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Table 3 BRCA1/BRCA2 truncating mutations, novel and non-truncating variants affect the gene products (Continued)
14 E2369EfsX23 Stop cod2391 c.7105insA 7333insA NR AB98 Br (35) Br EO-FH Argentina
18 D2723H p. Asp2723His c.8169 G>C 8397 G>C CU AB31 Ov (38) No EO E
D, deleterious; CU, clinically unknown importance; NR, Not Reported in Breast Information Core database(BIC) http://research.nhgri.nih.gov/bic/
Global, as defined in BIC or when reported in at least 3 continents ethnic groups in HapMap; E, European; As, Asian; A-A African-American; L-A, Latin American;
N-A, Native-American; A-C America-Caucasian; NE/ME, Near Eastern/Middle Eastern;
The DNA sequence numbering of BRCA1and BRCA2 sequence variants is based on recomendations of the Human Genome Variation Society (HGVS, translation
initiation codon ATG= 1) BRCA1:genomic sequence:L78833; RNA sequence: U14680; BRCA2 genomic sequence: NW_001838072; RNA sequence: NM_001838072
In bold, novel mutations not previously reported.
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negative probands selected for age within 40 years at diag-
nosis was 6/37 (16.2%). This falls within the 15-31% range
reported in the literature for EO BOC with FH [33-36],
but is in contrast with the lack of mutations reported in
EO Chilean patients without FH [37]. The published data
on the South American population [17,37,38] show lower
rates of mutation detection, while in agreement with
results from a study in the USA [31] and a large study in
high risk Hispanic family from USA [39] and also with an
study of Hispanic BOC from Colombia [40]. Differences
in mutation detection rates might reflect divergences in
the criteria of proband selection and in the methods of
analysis. In fact, the other South American [37,38] reports
were based on indirect mutation detection methods and
not on full sequencing; in contrast, we used direct sequen-
cing of all the amplicons along the BRCA1 and BRCA2
coding sequences and exon-intron boundaries.
It may be of interest to compare the deleterious muta-
tion rates of the young patients with no FH (16.2%) and
of the FH cases of similar age (within 40 years) in the
non-Ashkenazi and Ashkenazi groups (Table 3). Notably,
a pathogenetic mutation was found in 6/31 (19.4%) non-
Ashkenazi FH patients within 40 years of age (mean age
35.6 ± 4.8 years) and in 7/12 (58.3%) FH Ashkenazi cases
within the same age cutoff (mean 35.6 ± 2.8 years). The
recurrent Ashkenazi mutations were never detected in
non-Ashkenazi probands. BRCA1 c.66_67delAG, BRCA1
c.5263insC and BRCA2 c.5946delT were found in 7
(17.5%), 2 (5%) and 8 (20%) Ashkenazi probands, respect-
ively. Interestingly, BRCA2 c.5946delT was also found in
a non-Ashkenazi FH patient who could recall a great
grand mother of Ashkenazi origin. Conversely, only a
non-Ashkenazi pathogenetic mutation (Asp2723His in
BRCA2) was detected in one of 4 patients of Ashkenazi
origin included in the subset selected for early diagnosis
and no FH. This supports the full sequencing of EO Ash-
kenazi patients with no BOC FH.
With regard to disease association, the pathogenetic
mutations in BRCA1 occurred in 16/88 BC cases (18.2%),
5/24 OC cases (20.8%) and 2/22 BOC cases (9.1%), those
in BRCA2 in 13/88 BC cases (14.8%), 1/24 OC cases
(4.2%) and 1/22 BOC cases (4.5%). As expected, OC was
more frequent in BRCA1 carriers (21.7% vs 6.7%), and BC
in BRCA2 carriers (86.6% vs 65.2%) [30].Seven pathogenic mutations (18.4% of all the muta-
tions detected) were putatively novel: 5 in BRCA1
(21.7% for this gene), all with frameshifts generating stop
codons in exon 11, and 2 in BRCA2 (13.3% for this
gene), one with a frameshift at nt 2369, exon 14 (c7333
insA), the other (c.793 + 1delG) affecting the donor spli-
cing site nucleotide at IVS + 1 delG in intron 9 (Table 3).
The frequency of the common non-pathogenic variants
and synonyms was in agreement with that reported in the
BIC. The mutations reported in BIC as CU that we
detected in multiple patients as homozygous (in paren-
thesis number of cases) and/or in association with dele-
terious mutations, such as p. Gln356Arg, IVS7+ 36 C>T,
IVS7+ 41 C>T, IVS14-63 C>G, and IVS18+ 66 G>A in
BRCA1 and p. Val2171Val (9), p. Ala2466Val (4), IVS8+
56 C>T, IVS9+ 65delT, IVS10+ 12delT, and IVS11+ 80
delTTAA (1) in BRCA2 most probably represent non-
pathogenic variants. Furthermore, based on prediction
programs, homozygous status, detection in multiple unre-
lated patients and/or association with pathogenic muta-
tions, 10 variants found in the present study and not
reported in the BIC can be considered non pathogenic.
These include p. Val122Asp, p. Gln139Lys, IVS7+38 T>C,
IVS7+ 49 del 15 bp, in BRCA1 and c*110 A>C at 3'UTR
in BRCA2 (two other novel BRCA2 variants, i.e.,
IVS4+ 246 G>C and IVS4+364delT, located far from the
end of the exon 4 are reported here only as heterozygosity
markers).
Five of the 28 missense variants (Table 4) (i.e., p.
Arg7Cys, p. Cys61Gly, p. Arg71Gly, p. Tyr179Cys, and p.
Met1652Thr in BRCA1, p. Asp2723His in BRCA2) were
predicted to have an impact on protein structure upon
evaluation by SIFT and GVGD (Table 4). BRCA1 p.
Arg7Cys, differently from the other non-conservative var-
iants, has a rather low prediction score and was found in
two cases. The high prediction values for BRCA1 p.
Cys61Gly and BRCA1 p. Arg71gly agree with their previ-
ously reported pathogenicity [41,42] (Table 4). Few
reported data are available for BRCA2 p. Asp2723His [43].
BRCA1 p. Met1652Thr, located in the BRCT tandem re-
peat region is predicted to result in a large volume change
in rigid neighbourhood [44] but structural and functional
assays show normal peptide binding specificity and tran-
scriptional activity [45]. Tyr179Cys is also located in a
highly conserved region and is listed as clinically
Table 4 BRCA1/2 missense variants identified in 94 (non Askenazi) Argentinean breast/ovarian cancer cases
HGVS : Protein: DNA BIC: Status N° Carrier (%) Co-occurrence with deleterious Prediction SIFT GVGD grade refSNP
BRCA1
p. Arg7Cys c.19C> T CU 2(1.1) - NT C15 rs144792613
p. Cys61Gly c.181 T >G D 1 (1.1) - NT C65 -
p. Arg71Gly c.211A>G D 1 (1.1) - NT C65 -
p. Val122Asp c.365 T >A NR 5 (5.3) BRCA2 T C0 -
p. Gln139Lys c.415C>A NR 6 (6.3) - T C0 -
p. Tyr179Cys c.536A>G CU 1 (1.1) BRCA1 [30] (AB80) NT C35 rs56187033
p. Gln356Arg c.1067A>G CU 10 (10.6) BRCA1/BRCA2# T C0 rs1799950
p. Phe486Leu c.1456 T > C CU 1 (1.1) BRCA1 [30] (AB80) T C0 rs55906931
p. Val525Ile c.1573 G>A CU 1 (1.1) - T C0 rs80357273
p. Asn550His c.1648A>C CU 1 (1.1) BRCA1 [30] (AB80) NT C0 rs56012641
p. Asp693Asn c.2077 G>A CN 8 (8.5) BRCA1 T C0 rs4986850
p. Pro871Leu c.2612C> T CN 29 (30.9) BRCA1/BRCA2# T C0 rs799917
p. Lys898Glu c.2692A>G CU 1 (1.1) BRCA2 T C0 rs80357420
p. Met1008Ile c.3024 G>A CU 1 (1.1) BRCA1 [30] T C0 rs1800704
p. Glu1038Gly c.3113 G>A CN 33 (35.1) BRCA1/BRCA2# T C0 rs16941
p. Ser1040Asn c.3119 G>A CU 1 (1.1) BRCA1 [31] T C0 rs4986852
p. Asp1131Glu c.3393C>G NR 1 (1.1) BRCA2 T C0 -
p. Lys1183Arg c.3548A>G CN 34 (36.2) BRCA1/BRCA2# T C0 rs16942
p. Ile1275Val c.3823A>G CU 8 (8.5) - T C0 rs80357280
p. Glu1586Gly c.4757A>G NR 1 (1.1) - NT C0 -
p. Ser1613Gly c.4837A>G CN 33 (35.1) BRCA1/BRCA# T C0 rs1799966
p. Met1652Thr c.4955 T >C CU 1 (1.1) - NT C25 rs80356968
BRCA2
p. Tyr42Cys c.125A>G CU(BIC) 1 (1.1) - T C0 rs4987046
p. Asn289His c.865A>C CN 5 (5.3) BRCA2 NT C0 rs766173
p. His372Asn c.1114C>A CN 24 (4.2) BRCA1/BRCA2# T C0 rs144848
p. Arg858Ile c.2578 G> T NR 1 (1.1) BRCA2 T C0 -
p. Asn991Asp c.2971A>G CN 4 (4.2) BRCA2 T C0 rs1799944
p.Q1063K c.3187C>A NR 1 (1.1) - T C0 -
p. Asp1420Tyr c.4258 G>A CN 1 (1.1) BRCA2 [32] T C0 rs28897727
p. Met1915Thr c.5744 T > C CU 1 (1.1) - T C0 rs4987117
p. Ser2098Phe c.6749C> T CU 1 (1.1) - T C0 rs80358867
p. Arg2108His c.6323 G>A CU 1.(1.1) - T C0 rs35029074
p. Ala2466Val c.7397C> T CU 37 (39.4) BRCA1/BRCA2# NT C0 rs169547
p. Asn2486Lys c.7919 T >G NR 1(1.1) - T C0 -
p. Ile2490Thr c.7469 T > C CU 6 (6.3) - NT C0 rs11571707
p. Asp2723His c.8167 G>C CU 1 (1.1) - NT C65 rs41293511
p. Ile3412Val c.10690A>G CU 3 (3.2) - T C0 rs1801426
NR, Not Reported CU, Clinically Unknown; CN, clinically not important, in Breast Information Core database (BIC), http://research.nhgri.nih.gov/bic/;
In bold missense predict deleterious; NT, Not Tolerated; T, Tolerated; Align-GVGD grade between C0 and C65; Co-occurrence: # two or more patients.
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Tyr179Cys co-occurred with two other missense muta-
tions, i.e., Phe486Leu and Asn550His, in an FH patient
affected with pagetoid BC (AB80). These 3 mutations,already reported to occur together, may constitute a rare
haplotype [46] [brca.iarc.fr/LOVD].
In agreement with the complex population history of
Argentina, the BRCA1/2 mutations detected in this BOC
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backgrounds (Figure 1 and online Additional file 1: Table
S1 and Additional file 2: Table S2). Of the 96 detected
variants, 25 (26%) are not reported in the BIC, in Hap-
Map [47] and in the current literature, and are thus pu-
tatively unique for Argentina, 17 (17.7%) were reported
worldwide (at least 3 continents), 4 (4.2%) were reported
only in Latin-America. The remaining variants comprise
mutations previously detected in Europe, Asia and
North America. (Additional file 1: Table S1 and Add-
itional file 2: Table S2). The putative Latin American
variants include p. Ile2490Thr in BRCA2, a modestly
penetrant variant that might contribute to sporadic
breast cancer risk, listed as CU in the BIC, originally
described in a Caribbean patient [48] and reported al-
most 100 times in the BIC, frequently associated to
Latin American probands. In this line, several novel var-
iants were previously observed in Argentina in genes
related to other hereditary syndromes and might be
regarded as putatively regional or influenced by founding
events, [49-51]. In the present case series this mutation
recurred in six cases (Table 4, Figure 1)
Two other mutations related to South American ethni-
city deserve mention: 1) BRCA1 IVS7 + 37 del14bp
(TTTTCTTTTTTTTT), not listed in BIC but found in
10/42 families from Uruguay (including one with aFigure 1 Worldwide occurrence of 96 BRCA1/2 variants detected in 9
BIC or when reported in at least 3 continents in HapMap or in references; A
Ashk, Ashkenazi; E, European; LA, Latin American; NA, Native American; NEpathogenetic mutation in BRCA2) [38], and in a patient
from Chile [37]; and 2) BRCA2 IVS16-14 T>C, reported
in a patient from Uruguay [38] and detected in 31 of our
patients (including 4 with identified pathogenic
mutations).
Conclusions
The present study is the first reporting the spectrum of
BRCA1 and BRCA2 mutations in an Argentinean BOC
series, based on the analysis of the coding sequences and
exon-intron boundaries of both genes. Given that the
rates of BC incidence and mortality in Argentina are
among the highest in the world [23,24], a better under-
standing of the impact of BRCA1/BRCA2-related disease
in Argentinean BOC patients is important for the imple-
mentation of prevention and/or early detection strat-
egies. In our case series selected for early diagnosis with
no FH or for FH independently of age at diagnosis, the
overall detection rate of bona fide pathogenetic muta-
tions was quite high (38/134, 28.3%). This could rise to
35.8% (48/134) including the missense mutations sus-
pected to confer increasing risk of breast cancer.
Although global and European sequence variants con-
tribute to near 45% of the detected BRCA1/2 variation,
the significant fraction of new variants putatively unique
for Argentina detected in the present study might4 non-Ashkenazi Argentinean BOC patients. Global, as defined in
, African; AA, African American; AC, American Caucasian; As, Asian;
/ME, Near Eastern/Middle Eastern; ND, not determined.
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http://www.springerplus.com/content/1/1/20suggest the presence of a Native American genetic com-
ponent, not yet genetically characterized, that it in re-
cent centuries has come to admixture with alleles mostly
of European origin.
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